Vimseltinib
Payments companies reported to CMS as associated with Vimseltinib. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vimseltinib, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vimseltinib
These are the largest totals companies reported as associated with Vimseltinib. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Vinod Ravi | Houston, TX | Medical Oncology | $11,548.95 |
| Robert Randall | Sacramento, CA | Orthopaedic Surgery | $9,382.46 |
| Gabriel Tinoco Suarez | Columbus, OH | Medical Oncology | $7,617.92 |
| William Tap | New York, NY | Hematology & Oncology | $6,562.45 |
| Dale Shepard | Cleveland, OH | Hematology & Oncology | $6,439.79 |
| Gina D Amato | Atlanta, GA | Hematology & Oncology | $5,458.15 |
| Kamalesh Sankhala | Beverly Hills, CA | Medical Oncology | $5,097.85 |
| Andrew Wagner | Boston, MA | Hematology & Oncology | $4,832.64 |
| Mark Agulnik | Los Angeles, CA | Medical Oncology | $4,569.03 |
| Vinu Madhusudanannair-Kunnuparampil | San Antonio, TX | Hematology & Oncology | $3,916.28 |
Prescribed Vimseltinib?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.